Now in Europe
Active Pharmaceutical Ingredient:
Beta-blocking agents, selective
- Landiolol hydrochloride is indicated for supraventricular tachycardia and for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable.
- Landiolol hydrochloride is also indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention.
- Landiolol is not intended for use in chronic settings.
One vial of 50 ml contains 300 mg powder for solution for infusion.
Additional dosage options:
Rapibloc® 20 mg/2 ml concentrate for solution for injection (5 ampules per pack)
Learn more about how Rapibloc® can support physicians in managing acute atrial fibrillation.
Brand names may vary by country: Rapibloc, Raploc, Landiobloc, Runrapiq